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ABSTRACT 
 
Bone tissue is densely innervated, and there is increasing evidence for a neural control of 
bone metabolism. Semaphorin-3A is a very important regulator of neuronal targeting in the 
peripheral nervous system, as well as angiogenesis, and knockout of the Semaphorin-3A 
gene induces abnormal bone and cartilage development. We analysed the spatial and 
temporal expression patterns of Semaphorin-3A signaling molecules during endochondral 
ossification, in parallel with the establishment of innervation. We show that osteoblasts and 
chondrocytes differentiated in vitro express most members of the Semaphorin-3A signaling 
system (Semaphorin-3A, Neuropilin-1, Plexins-A1 and -A2). In vitro, osteoclasts express 
most receptor chains but not the ligand. In situ, these molecules are all expressed in the 
periosteum and by resting, pre-hypertrophic and hypertrophic chondrocytes in ossification 
centers before the onset of neurovascular invasion. They are detected later in osteoblasts and 
also osteoclasts, with differences in intensity and regional distribution. Semaphorin-3A and 
Neuropilin-1 are also expressed in the bone marrow. Plexin-A3 is not expressed by bone cell 
lineages in vitro. It is detected early in the periosteum and hypertrophic chondrocytes. After 
the onset of ossification, this chain is restricted to a network of cell processes in close 
vicinity to the cells lining the trabeculae, similar to the pattern observed for neural markers at 
the same stages. After birth, while the density of innervation decreases, Plexin-A3 is strongly 
expressed by blood vessels on the ossification front. In conclusion, Semaphorin-3A signaling 
is present in bone and seems to precede or coincide at the temporal but also spatial level with 
the invasion of bone by blood vessels and nerve fibres. Expression patterns suggest Plexin-
A3/Neuropilin-1 as a candidate receptor in target cells for the regulation of bone innervation 
by Semaphorin-3A. 
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INTRODUCTION 
 
 
Early work as well as recent immunocytochemical studies have highlighted the rich 
innervation of bone (Calvo and Forteza-Vila, 1969; Serre et al., 1999). The expression of 
neuromediators in skeletal nerve fibres, and of their receptors in osteoblasts and osteoclasts 
has been established. The presence in bone of cell processes labeled with neural tip markers 
like synaptophysin has also been documented. Overall, these data provide evidence for the 
existence of functional nerve fibres within the bone tissue (Gronblad et al., 1984; Hohmann et 
al., 1986; Bjurholm et al., 1988; Serre et al., 1999). Some of these nerve fibres are in contact 
with cells lining the trabeculae (osteoblasts and osteoclasts), suggesting a direct control of 
bone cell function (Serre et al., 1999). Several studies have indeed shown evidence for a 
neural control of bone growth. Developmental growth in the rat foot is reduced after surgical 
denervation (Edoff et al., 1997). The remodelling of bone is also affected by surgical or 
chemical sensory and sympathetic denervations in rat (Sandhu et al., 1987; Hill et al., 1991; 
Cherruau et al., 1999). Furthermore, a leptin-dependent regulation of bone mass by the 
central nervous system has been demonstrated in mice, which appears to be mediated by 
sympathetic innervation (Ducy et al., 2000; Takeda et al., 2002). The role of sympathetic 
innervation in bone remodelling is also supported by the changes in bone mass observed in 
mice deficient in genes coding for dopamine β-hydroxylase, dopamine transporter and Y2 
receptors (Bliziotes et al., 2000; Baldock et al., 2002; Takeda et al., 2002). 
As early as embryonic day (E)15, nerve fibres appear in the perichondrium of the diaphysis 
of rat long bones. They become functional at E18-19, when neural tips are formed and 
neuropeptide expression starts (Sisask et al., 1995; Sisask et al., 1996). There is little 
understanding of the molecular mechanisms by which neurons reach their targets in bones. In 
the central nervous system, many studies described several families of proteins which are 
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involved in wiring and allow axons and dendrites to locate and reach their appropriate 
targets. The most prominent families of neural signaling molecules are Semaphorins, Netrins, 
Slits and Ephrins. The Semaphorins, a large family of cell surface and secreted guidance 
molecules, is one of the best understood. In particular, it has been shown that Semaphorin-3A 
(Sema-3A) signaling is very important for neuronal targeting in the peripheral nervous 
system (PNS), as shown for trigeminal and dorsal root ganglia which are involved in bone 
innervation (Kitsukawa et al., 1997; Taniguchi et al., 1997; Ulupinar et al., 1999). Sema-3A, 
a soluble molecule, signals through multimeric receptors always combining at least one of 
the 3 plexins (Plx) and neuropilin-1 (NP-1). NPs do not appear to have a signaling function. 
Plx contribute to both ligand specificity and signal transduction, activating RhoA through 
poorly known mediators (Goshima et al., 2002). Recently the expression of Sema-3A and 
NP-1 was demonstrated in osteoblast and osteoclast cell lines, and NP-1 was shown to be 
expressed in bone (Togari et al., 2000; Harper et al., 2001). Furthermore, abnormal bone and 
cartilage development, with vertebral fusions and partial rib duplication, has been observed 
after a targeted mutation of Sema-3A in mouse, indicating that this signaling pathway may 
play a role in bone development (Behar et al., 1996). 
The aim of our study was to investigate the expression of the molecules in the Sema-3A 
signaling network during skeletal development, focusing on the spatial and temporal 
relationship with nerve fibre growth. 
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 RESULTS 
 
Multiple bone cell lineages express components of the Semaphorin axon guidance 
system 
Messenger RNA for Sema-3A, NP-1, Plx-A1 and Plx-A2 but not Plx-A3 were detected in 
osteoblastic cells. They were also present, with the exception of Sema-3A, in differentiated 
osteoclasts (fig. 1A). Sema-3A, NP-1 and Plx-A1 and -A2 mRNA are expressed at all stages 
of chondrocyte differentiation, including the final hypertrophic stage, reached under the 
highest dose of BMP-2 (fig. 1B). Plx-A3 was not detectable in chondrocytes at any stage. As 
shown on figure 2, NP-1, Plx-A1 and A2 proteins are expressed by both osteoblasts and 
osteoclasts. Sema-3A expression was only detected in osteoblasts, confirming RT-PCR data. 
Only a very faint staining was observed in MC 615 cells for all markers (not shown). 
 
Sema-3A and its receptor chain, NP-1, have the same pattern of expression during 
endochondral ossification 
We observed that Sema-3A and NP-1 displayed nearly identical patterns of expression at all 
stages of bone development. At E17 Sema-3A (fig. 3C) and NP-1 (not shown) were detected 
in the outer perichondrium of the diaphysis and metaphysis, and in the pre-hypertrophic and 
hypertrophic chondrocytes within the future primary ossification center (fig.3 C, enlargement 
in D). Staining was also present in resting chondrocytes within the epiphysis, the site of the 
future secondary ossification center (fig. 3C). At E19 NP-1 (fig. 3F) and Sema-3A (not 
shown) presented a patchy staining in the periosteum of the diaphysis, restricted to the area 
lining the primary ossification center. At this stage NP-1, but not Sema-3A, was also 
expressed in the bone collar (fig. 3F) and in blood vessels in the primary ossification center 
(Fig. 3G). At E21, staining for Sema-3A (fig. 3H) and NP-1 (not shown) was located in 
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osteoblasts and in the bone marrow and blood vessels, in trabecular bone and only for Sema-
3A in the endosteum (fig. 3H). NP-1 (fig. 3J) and Sema-3A (fig. 3K) at P14 were both still 
located in osteoblasts lining the bone trabeculae but only under the growth plate. Both 
molecules were also expressed in pre-hypertrophic and hypertrophic chondrocytes of the 
growth plate (NP-1: Fig. 3L, enlarged in M and M; Sema-3A: data not shown). At P14, 
Sema-3A (fig. 3O) and NP-1 (fig. 3P) were also detected in large multinucleated (DAPI 
staining of nuclei in insets) osteoclasts along the trabeculae under the growth plate. 
 
Co-receptors Plexins A1 and A2 are expressed by chondrocytes and osteoblasts 
At E17, Plx-A1 was expressed in the perichondrium of the diaphysis and the metaphysis (fig 
4A), in hypertrophic chondrocytes at mid-diaphysis and also in the resting chondrocytes in 
the epiphysis (not shown). Plx-A1 was still present at E19 in hypertrophic chondrocytes (fig 
4B), especially those facing the osteogenic perichondrium. It was expressed at lower levels in 
the periosteum and by bone collar forming osteoblasts (4B, short arrows) and in the primary 
ossification center (not shown). Plx-A1 was expressed by osteoblasts lining all bone 
trabeculae at E21 (fig. 4C, arrows) and only those under the growth plate at P14 (fig. 4D, 
arrows). At the latter stage, it was also expressed by periosteal osteoblasts (fig. 4D, 
arrowheads), by some osteocytes (fig. 4D, dotted line circles) and in osteoclasts (fig. 4E). At 
E17, Plx-A2 was expressed in hypertrophic chondrocytes, in resting chondrocytes of the 
epiphysis and also at lower levels in the perichondrium (fig 4F). At E19, staining extended to 
the primary ossification center (not shown). At E21, Plx-A2 (Fig. 4G) was present in the 
periosteum (short arrows) and in some osteoblasts (long arrows) and osteocytes (dotted line 
circles). At P14, expression of Plx-A2 (fig 4H) was mostly restricted to endosteal (arrows) 
and periosteal osteoblasts (short arrows) and osteocytes (dotted line circles). At this stage it 
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was also detected in a few osteoblasts and in osteoclasts under the growth plate (fig. 4I). Both 
markers were also expressed by other cell types in the marrow and the periosteum (4D, H). 
 
Plx-A3 presents a restricted pattern of expression during endochondral ossification 
At E17, Plx-A3 was expressed in the perichondrium of the metaphysis (fig. 5A), where some 
profiles seemed to outline blood vessels (5A, arrows), and by hypertrophic as well as some 
resting chondrocytes (not shown). Staining at E19 (fig. 5B) was located in discrete profiles 
within the periosteum at the mid-diaphysis, some of which suggestive of vascular staining 
(5C, arrow). Plx-A3 was also detected in the bone collar (5D) and in hypertrophic and at 
lower levels in resting chondrocytes (not shown). No labeling was observed at this stage 
within the primary ossification center. At E21, Plx-A3 was expressed in the secondary 
spongiosa as a loose network along bone trabeculae and in endothelial cells (fig. 5E, enlarged 
in F). It was also present in the periosteum and hypertrophic and some resting chondrocytes 
(not shown). At P14, Plx-A3 was strongly expressed in endothelial cells of vascular buds in 
the ossification front under the growth plate (fig. 5G and H), and in capillaries in the 
metaphysis (fig. J). 
 
The pattern of expression of neural cell markers in developing rat femur parallels the 
development of endochondral ossification 
To correlate the in vivo expression of Sema-3A and its receptor subunits with the appearance 
of nerve fibres, we analysed the expression of nerve markers during bone development. 
Neurofilament heavy chain (NH) is a general nerve marker, while tyrosine hydroxylase (TH), 
an enzyme involved in the synthesis of catecholamines such as noradrenalin, is a specific 
marker for sympathetic nerves fibres. The staining patterns of both markers were identical at 
all development stages, although TH gave a higher background at late stages. At E17, both 
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markers were expressed only in the perichondrium of the metaphysis (fig. 6A, F). At E19, 
NH and TH positive fibres were found in the periosteum of the diaphysis along the primary 
ossification center (fig. 6B, G). At this stage, we also found NH and TH labeling in the bone 
collar (fig. 6B, G, long arrows). At E21, the nerve fibres were located along the bone 
trabeculae in the diaphysis (fig. 6C, H, short arrows), in close vicinity to osteoblasts and 
lining cells. At P14, labeling was weaker in bone and was still present in the periosteum of 
the diaphysis (NH in fig. 6E, not shown for TH). 
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DISCUSSION 
 
Three functional receptor complexes have been described for Sema-3A: NP-1/Plx-A1, NP-
1/Plx-A2, NP-1/Plx-A3 (Nakamura et al., 2000; Raper, 2000). These complexes also bind 
other ligands in a competitive fashion: Sema-3B, 3C and 3F, and vascular endothelial growth 
factor-165 (VEGF165). Target genes and signal transduction pathways for this signaling have 
not been fully elucidated, but in neural cells are known to involve the reorganisation of the 
cytoskeleton via Rho GTPases, which enables axonal guidance (Castellani and Rougon, 
2002). In this study, we show that all components of the Sema-3A signaling system are 
expressed in mature stages of all 3 bone cell lineages (chondrocytes, osteoblasts and 
osteoclasts), with the exception of Plx-A3. Although osteoclastic cells from RAW 264.7 
cultures do not express Sema-3A, we found labelling in resorbing osteoclasts within the bone 
tissue. Others reported its expression in osteoclast-like cells from human bone marrow 
cultures (Togari et al., 2000). This may reflect specificities of immortalised cell lines and/or 
culture conditions, which could also explain the low levels/absence of Sema-3A signaling 
proteins in the MC 615 chondrogenic cells, in spite of messenger expression. It was 
previously reported that MC3T3-E1 osteoblastic cells express NP-1 mRNA and that several 
human osteoblastic cell lines express Sema-3A mRNA and protein (Togari et al., 2000; 
Harper et al., 2001). Expression of NP-1 mRNA was also shown in human osteoarthritic 
cartilage (Enomoto et al., 2003). To the best of our knowledge we are the first to show the 
expression of Plexins-A1 and –A2 in osteoblasts, osteoclasts and chondrocytes, of NP-1 in 
osteoclasts, and of Sema-3A in chondrocytes.  
During bone development, we first observed Sema-3A and all components of its receptor 
system in pre-hypertrophic and hypertrophic chondrocytes in ossification centers, and also in 
the facing periosteum, before and after the onset of endochondral ossification and vascular 
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invasion. We found in particular that Plx-A1 is more strongly expressed by the outermost 
layer of chondrocytes of the mid-diaphysis, in direct contact with the osteogenic 
perichondrium (fig. 4B). Such “borderline” chondrocytes have been suggested to interact 
with perichondral osteoblasts for the regulation of ossification (Bianco et al., 1998). Thus, 
Sema-3A signaling precedes or coincides with the invasion of bone by blood vessels and 
nerve fibres (Table 2). At later stages, Sema-3A and its receptor components (except Plx-A3) 
are co-expressed by osteoblasts and osteoclasts, with regional differences. Such co-
expression is compatible with an autocrine/paracrine pathway, such as has been shown for 
instance in breast carcinoma cells (Bachelder et al., 2003). However, expression of Sema-3A 
receptors in bone is not restricted to osteoblast and osteoclasts, but is also found in blood 
vessels and probably nerve processes. Thus, Sema-3A signaling molecules are in a position to 
modulate the vascularisation of bone, and the innervation of osteoblasts and osteoclasts 
during bone development and remodelling. 
In keeping with a number of recent studies showing evidence that bone modelling and 
remodelling are controlled by the nervous system (Sandhu et al., 1987; Hill et al., 1991; 
Edoff et al., 1997; Cherruau et al., 1999; Takeda and Karsenty, 2001; Takeda et al., 2002),  
we previously showed a dense innervation of bone in close contact with osteoblasts and 
osteoclasts, although no typical synapses were observed (Serre et al., 1999). We observed 
here the same labeling pattern and density for NH, a general nerve marker and TH, a specific 
marker for sympathetic fibres. This suggests that the sympathetic system, which is known to 
innervate blood vessels and suspected to play a part in the regulation of bone remodelling, is 
the major one in bone, at least at the stages that we investigated (Ducy et al., 2000; Takeda et 
al., 2002; Levasseur et al., 2003). In ossified areas, we found staining for NP-1 not only in 
osteoblasts and osteoclasts, but also in endothelial cells and within the bone marrow. Such 
generalised expression did not allow identification of a “network” pattern similar to nerve 
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markers; nonetheless, expression of NP-1 in nerve processes is amply documented in the 
literature (Yu and Bargmann, 2001). In contrast, the expression pattern of Plx-A3 in 
developing bone strikingly parallels the one observed for nerve markers from E17 to E21. It 
is, however, also localised in the endothelial cells of capillaries, particularly at the 
ossification front in later stages. Peripheral nerves and blood vessels have similar patterns of 
development in the forelimb, and Sema-3A may function as a common signal molecule for 
the establishment of the two systems (Bates et al., 2003). Our unablility to detect Plx-A3 
expression within the primary ossification center at E19 could be explained by a down-
regulation allowing vascular penetration (see below). Overall, our observations suggest that 
Plx-A3 is the candidate partner of NP-1 for the regulation of neurovascular patterning by 
Sema-3A.  
Sema-3A has been shown in numerous studies to be a repulsive neural guidance cue, crucial 
for the normal patterning of nerves fibres in vivo (Schwarting et al., 2000; Kawasaki et al., 
2002). However, this action can be counteracted by competitive inhibitors. For instance, the 
competition for NP-1 occurring between Sema-3A and VEGF165, which is expressed by 
human hypertrophic, but not proliferative chondrocytes of the growth plate (Petersen et al., 
2002), seems to play a key role in mechanisms of innervation and angiogenesis. The effect of 
VEGF165 on both peripheral nerves and blood vessels opposes the effect of sema-3A 
(Nakamura et al., 2000). VEGF165 enhances endothelial cell survival and mobility and 
increases axonal outgrowth and neural survival in vitro (Castellani and Rougon, 2002; 
Petersen et al., 2002; Enomoto et al., 2003). In contrast, Sema-3A inhibits endothelial cells 
mobility and survival, as well as axonal outgrowth (Deckers et al., 2000; Castellani and 
Rougon, 2002; Bachelder et al., 2003; Serini et al., 2003). An hypothesis suggested by our 
observations on early bone development is that the Sema-3A/Plx-A3/NP-1 pathway would 
inhibit neurovascularisation of the cartilage anlage early in skeletal development. This block 
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could be removed later and locally by the down regulation of key receptor chains (e.g. Plx-
A3), the elimination of Sema-3A producing cells (e.g. hypertrophic chondrocytes, cf. POC at 
E19, Table 2) or by the expression of competitors of Sema-3A (such as VEGF165), for 
instance by perichondral cells and hypertrophic chondrocytes. Inhibition of Sema3A 
signaling would then allow blood vessel and nerve fibre invasion of the diaphysis, and thus 
the onset of endochondral ossification together with the start of local neural and/or vascular 
regulation of bone formation. Later, during the ossification process, Sema-3A may provide a 
repulsive guidance allowing the growing nerve fibres to be directed to their targets in the 
bone tissue. However, other guidance sytems are certainly involved in bone neurovascular 
development and are likely to interfere with the Sema-3A pathway. 
In conclusion, we show that the Sema-3A signaling network appears to be well positioned to 
regulate the development of bone innervation, and perhaps other aspects of bone 
development and remodelling. 
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MATERIALS AND METHODS 
 
In vitro models 
We analysed the expression of the Sema-3A signaling molecules in in vitro models of 
osteoblasts, osteoclasts and chondrocytes. In mature (day 15) rat calvaria (RC) cell cultures, 
osteoprogenitors form bone colonies expressing high levels of osteoblast markers, 
osteocalcin and bone sialoprotein (Malaval et al., 1999)(Fig. 1A, 2B). As an osteoclast 
model, we used the RAW 264.7 cell line, which, when treated with the cytokine RANKL, 
fully differentiate in multinucleated osteoclast-like cells expressing calcitonin receptor and 
tartrate resistant acid phosphatase (Hsu et al., 1999)(Fig 1A, 2D). As a chondrocyte model 
we used the immortalised mouse cell line MC 615, which can differentiate into hypertrophic 
chondrocytes when treated with BMP-2, as documented by the concomitant expression of 
Collagen Xα1 and osteocalcin (Fig 1B)(Valcourt et al., 2002). 
 
In situ model 
To analyse the spatial expression of sema-3A and NP-1 during bone development, we 
performed immunocytochemical studies on developing rat femurs at days E17 and E19 
(beginning of endochondral ossification), at E21 (birth) and 14 days after birth (P14, end of 
the endochondral ossification). At E17 the bone is still a cartilage model in the center of 
which (mid-diaphysis) some chondrocytes become hypertrophic. It is limited by a layer of 
undifferentiated osteogenic cells, the perichondrium (termed periosteum at later stages). At 
E19 the bone collar has formed, and vascular invasion and endochondral ossification has 
begun in the mid-diaphysis (primary ossification center). The growth plates are formed soon 
after E19, separating the epiphysis from the metaphysis. In fully developed bone, trabecular 
bone tissue is restricted to the metaphysis and the epiphysis; the midshaft (diaphysis) 
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contains only bone marrow. At E21 vascular invasion of the epiphysis and development of 
the secondary ossification center has begun, and is well established at P14. Histologically, 
osteoblasts are observed lining the outer cortical bone, as the basal cell layer of the 
periosteum (fig. 3A, short arrows). They also line the inner cortical bone (endosteum) and are 
present as cuboidal cells along bone trabeculae in the metaphysis (fig. 3B, short arrows). 
Osteoclasts are larger, multinucleated cells, usually in direct contact with the bone matrix 
(Fig 3A, B, long arrows). 
 
Cell culture 
Culture reagents were from Sigma (Saint-Quentin Fallavier, France) unless otherwise 
indicated. 21 days pregnant female Wistar rats were killed by cervical dislocation, in 
accordance with the local Ethical Committee recommendations, and the fetuses were 
collected through C-section. Fetal rat calvaria (RC) cells were enzymatically isolated by 
sequential digestion with collagenase as described previously (Bellows et al., 1986; (Malaval 
et al., 1999); populations obtained from digests II through V were kept and plated separately. 
After 24 h, cells were trypsinised (0.01% trypsin in citrate saline), counted, populations II-V 
were pooled, and cells were plated at 3 x 103 cells/cm2 in 35 mm dishes for RNA isolation 
and on 1cm2 glass coverslips for immunostaining. RC cells were grown in α-MEM medium 
containing antibiotics, 10% FBS, 50μg/ml ascorbic acid, and 10 mM sodium β-
glycerophosphate. The medium was changed every 2-3 days. All dishes were incubated for 
15 days at 37°C in a humidified atmosphere of 95%air/5% CO2. The RAW 264.7 monocytic 
cell line was cultured in 25cm2 flasks or on glass coverslips, in DMEM medium 
supplemented with 10% fetal calf serum, 1% penicillin/streptomycin, 1% glutamate and 0.5% 
fongizone. The cultures were kept for 6 days to differentiate into osteoclasts in whole 
medium described above supplemented with 30ng/ml Rank Ligand (kindly provided by 
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Amgen, Thousands Oaks, CA, USA). The mouse chondrogenic MC 615 cell line has been 
characterised previously (Mallein-Gerin and Olsen, 1993; Valcourt et al., 2002). MC 615 
cells were maintained in 1:1 high glucose DMEM/Ham’s F-12 containing 10% FBS and 
supplemented with 2mM L-glutamine, 100 units/ml penicillin, 100µg/ml streptomycin (all 
product from in Vitrogen). For differentiation into hypertrophic chondrocytes, MC 615 cells 
were grown for 3 days in flasks or on glass coverslips as above, except that FBS was reduced 
to 1% and BMP-2 (0-100ng/ml) was added to the medium. Recombinant human BMP-2 was 
produced and purified by Genetics Institute, Inc. (Cambridge, MA, USA). The culture 
medium supplemented with BMP-2 was replaced each day. At the end of the culture time, all 
cell types were either processed for RNA isolation or fixed and permeabilised for 
immunostaining. 
 
RNA isolation and RT-PCR 
Cells were scraped in lysis buffer and total RNA was isolated using the RneasyR minikit 
(Qiagen SA, Courtaboeuf, France). 2μg of total RNA were reverse-transcribed using 
Omniscript reverse transcriptase from Qiagen SA (Courtaboeuf, France) and oligo (dT)12-18 
primers (Amersham Pharmacia Biotech, Orsay, France). Polymerase Chain Reaction (PCR) 
was performed using 2μl (equivalent to 0.2µg of RNA) of each RT reaction as template with 
the HotStarTaqTM DNA polymerase kit (Qiagen SA). PCR primers were designed from 
published DNA sequences (Table I). Efficiency and specificity of amplification with the 
designed primer pairs were controlled using mRNA isolated from mouse or rat brain. 
 
Tissue processing 
The fetuses were collected as described in the Cell Culture section. The femurs of fetuses and 
born rats were rapidly excised and cleaned of skin and muscles, then cut longitudinally at the 
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diaphysis level (for E18 and older fetuses) and immediately fixed in 4% paraformaldehyde in 
0.1M phosphate buffer, pH 7.3 at 4°C for 24h (McKee et al., 1991). The samples were 
decalcified in 4% di-sodium ethylenediamine-tetraacetic acid (EDTA) for 1 up to 5 weeks 
before dehydratation through a graded ethanol series and embedded in paraffin. Sections 
(5μm) were cut on a Leica RM2145 microtome (Leica instruments, Heidelberg, Germany) 
and processed for immunocytochemistry. 
 
Immunocytochemistry 
Cultures on glass coverslips were fixed in 3.7% formaldehyde, permeabilised in –20°C 
methanol and stored in PBS. Cytoenzymology for TRAP activity in RAW cells was 
performed with a commercial kit (#386-A, Sigma). Sections from decalcified samples were 
laid on silanised slides and dried overnight at 37°C. After two baths of methylcyclohexane 
and rehydration, the sections were treated, along with coverslips, for 15min with 100mM 
glycine and 50mM ammonium chloride in Tris buffer, pH 7.6, in order to saturate free 
aldehydic groups. Endogenous peroxidase activity was blocked by incubation for 15min with 
1% sodium azide and 1.5% H2O2 in 50% methanol. Sections and cultures were then 
incubated overnight at 4°C with primary antibodies diluted in Tris Buffer Saline (TBS: Tris-
HCl 50mM pH: 7.6, 0.9% NaCl, 0.01% BSA) containing 1% normal rat serum to saturate 
non-specific sites. All goat polyclonal antibodies against Sema-3A and its receptor 
components were purchased from Santa-Cruz Biotechnology (Santa-Cruz, CA, USA). On 
sections, the anti rat-Sema-3A (sc1148) and anti human-NP-1 (sc7240) were used at 2μg/ml, 
the anti human-Plx-A1 (sc10139) at 0.4µg/ml, the anti human-Plx-A2 (sc10144) at 4µg/ml 
and the anti human-Plx-A3 (sc10134) at 0.8µg/ml. The rabbit anti rat-Tyrosine Hydroxylase 
(TH) (AB151), used at 1/5000, and the rabbit anti rat-Neurofilament Heavy Chain (NH) 
(AB1991), used at 1/2000, were purchased from Chemicon (Temecula, CA, USA). The 
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production and use of the rabbit antiserum directed against bone sialoprotein (BSP) have 
been described previously ((Malaval et al., 1999) and references therein). Controls were 
incubated with non-immune goat or rabbit serum. For goat primary antibodies on sections, 
we used a second step incubation with a rabbit anti-goat IgG antibody (Dako, Copenhagen, 
Denmark) for 30 min. Both goat and rabbit antibody-antigen complexes were detected with a 
rabbit Dako EnVision + K4002 kit (Dako). For coverslips, the incubation time of primary 
antibodies was reduced to 30 minutes at room temperature, and the signal was enhanced by 
the use of a biotin labeled anti-goat secondary antibody with an additional incubation step 
with streptavidin-peroxidase. Labeling was revealed with 3-3’ diaminobenzidine 
tetrahydrochloride (DAB) (Sigma) in Tris buffer containing 0.01% H2O2. All washings were 
done with TBS containing 0.02% Triton X100. Some labeled sections were counter-stained 
either with toluidine blue or with the DNA labeling compound, 4’, 6 diamidino-2-
phenylindole (DAPI, Sigma); some unlabeled sections at P14 were stained with Goldner’s 
trichrome for histological visualisation. Sections were dehydrated, mounted in Xam (Gurr-
BDH Laboratory, Poole, UK) and then observed on a Leica DMRB microscope (Leica, Paris, 
France). Coverslips were mounted in Fluoprep (Biomérieux, Marcy l’Etoile, France). 
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Table 1: Primers sequences and PCR conditions.  
 
Target Origin Primer sequences (5’ to 3’) Accession Number 
Product 
length 
(bp) 
Number of 
cycles 
Annealing   
temperature 
(ºC) 
Sema-3A Rat GTGTTCCTTGG CCATATGCTC CAGCAGTTGAGCCAATGT CAG NM_017310 472 35 48 
NP-1 Mouse CTGGTGAGCCCTGTGGTCTATTCC ATATCATCCACAGCAATCCCACCG AF 018957 272 35 55 
Plx-A1 Mouse TCACTCACCTGGTGGTTCA CACAAAGCCAAACATGTCAGC D 86948 505 35 50 
Plx-A2 Mouse CATGTCTGAGAGACAGGTCACCA CCAGGTGAGATGCAGATGACTTG D 86949 360 35 55 
Plx-A3 Mouse  GCTGTTGATGGCAAGTCTGA GAAGGAGCACTGACAAAGC NM_008883 198 40 52 
ColXa1 Mouse GCAACTAAGGGCCTCAATGG GAGCCACTAGGAATCCTGAG NM_009925 596 35 57 
OCN Mouse CAAGTCCCACACAGCAGCTT AAAGCCGAGCTGCCAGAGTT X 04142 371 30 58 
OCN Rat AGGACCCTCTCTCTGCTCAC AACGGTGGTGCCATAGATGC X04141 294 25 60 
BSP Rat ATGGAGATGGCGATAGTTCG  TGAAACCCGTTCAGAAGGAC NM_012587 504 30 60 
CTR Mouse GTCTTGCAACTACTTCTGGATGC AAGAAGAAGTTGACCACCAGAGC U18542 255 40 55 
TRAP Mouse CTCTCTGACCACCTGTGCTTCCTC GAACCTCTTGTCGCTGGCATCGTG NM_007388 292 26 55 
GAPDH Mouse ATCACTGCCACCCAGAAGAC ATGAGGTCCACCACCCTGTT AK015422 443 25 57 
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Table 2 – Expression of Sema-3A signaling molecules during endochondral ossification. 
 
 
Stage Site Sema-3A/NP-1 Plx-A1/Plx-A2 Plx-A3 Nerve markers 
Periosteum + ++/+ + Along the metaphysis
E17 
HC ++ ++ + - 
Periosteum ++ + + Ubiquitous 
E19 
POC NP-1 + - - 
Periosteum ++ + + + 
Cortical bone + + + + E21 
Metaphysis ++ + + ++ 
Periosteum + + + + 
Cortical bone - Osteoblasts Osteocytes + + P14 
Metaphysis 
Osteoblasts and 
osteoclasts under 
the growth plate 
Osteoblasts (few 
for A2) and 
osteoclasts under 
the growth plate 
Endothelial 
cells under the 
growth plate 
Loose network  
in the marrow 
+: Expressed, -: Not detected. HC: Hypertrophic chondrocytes; POC: Primary ossification center. 
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LEGENDS OF FIGURES 
 
Figure 1: Expression of RNA for Sema-3A signaling molecules by osteoblasts, osteoclasts 
and chondrocytes in vitro. A: RT-PCR analysis of differentiation markers and Sema-3A 
signaling molecules in mature osteoblastic (15 days of culture) RC cell cultures and 
osteoclasts differentiated from RAW 264.7 cells under RANKL treatment for 6 days. B: RT-
PCR analysis of differentiation markers and Sema-3A signaling molecules in the mouse 
chondrogenic cell line MC 615 grown with BMP-2. OCN: osteocalcin, BSP: bone 
sialoprotein, CTR: calcitonin receptor, TRAP: tartrate-resistant acid phosphatase, CollXα1: 
collagen Xα1. 
 
Figure 2: Immunodetection of Sema-3A signaling molecules in osteoblasts and 
osteoclasts in vitro. Osteoblasts differentiated from RC cells (A, B, E, G, I, K) and 
osteoclast-like cells differentiated from RAW 264.7 cells (C, D, F, H, J, L) were 
immunolabeled for the antigens indicated. Controls (A, C) were incubated with non-immune 
antibodies. D: Cytoenzymology for the osteoclast marker TRAP. 
 
Figure 3: Immunodetection of sema-3A and NP-1 during endochondral development of 
rat femur. A and B: trichrome histological staining at P14, showing cortical (A) and 
trabecular areas (B); short arrows: osteoblasts, long arrows: osteoclasts (X2000). C: Sema-3A 
at E17; arrows: periosteum, dotted line: pre-hypertrophic and hypertrophic chondrocytes in 
mid-diaphysis, dotted circle: resting chondrocytes in the epiphysis (X100); mid-diaphysis 
enlarged in D. E: Non-immune control at E17. F: NP-1 at E19, diaphysis; short arrows: 
staining in the periosteum, long arrows: staining in the bone collar (X800). G: NP-1 at E19, 
primary ossification center; stars: blood vessels (X800). H: Sema-3A at E21, diaphysis; 
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arrows: labeled endosteum (X400). I: non-immune control at E21. J: NP-1 at P14, growth 
plate and ossification front (200X). K: Sema-3A labelled osteoblasts under the growth plate 
at P14 (X2000). L: NP-1 at P14, pre-hypertrophic and hypertrophic chondrocytes (1000X); 
selected areas enlarged in M and N. O: Sema-3A at P14, osteoclast near the ossification front 
(2000X). P: NP-1 at P14, osteoclast near the ossification front (2000X). Insets in O and P: 
counter-staining with DAPI for fluorescent nucleus detection. Sections K, L, M, and N were 
counter-stained with toluidin blue. BC: bone collar, GP: growth plate, P: periosteum, PHC: 
pre-hypertrophic chondrocytes, T: trabecula. 
  
Figure 4: Immunodetection of Plx-A1 and Plx-A2 during endochondral development of 
rat femur. A: Plx-A1 at E17, diaphysis (X400). B: Plx-A1 at E19, diaphysis along the 
primary ossification center; stars: hypertrophic chondrocytes, long arrows: “borderline” 
chondrocytes, short arrows: periosteal osteoblasts (X800). C: Plx-A1 at E21; arrows: 
osteoblasts (X1000). D: Plx-A1 at P14, metaphysis; long arrows: trabecular osteoblasts, short 
arrows: periosteal osteoblasts (X400). Selected area enlarged in inset; dotted line circles: 
osteocytes. E: PlxA1 at P14, osteoclast near the ossification front (2000X). F: Plx-A2 at E17; 
dotted line circle: hypertrophic chondrocytes (X100). G: Plx-A2 at E21, diaphysis; short 
arrows: staining in periosteum, long arrows: osteoblasts, dotted line circle: osteocytes  
(X600). H: Plx-A2 at P14, cortical bone of the diaphysis; long arrows: endosteal osteoblasts, 
short arrows: periosteal osteoblasts, dotted line circles: osteocytes (X600). I: PlxA2 at P14, 
osteoclast near the ossification front (2000X). J: Non-immune control at P14 (X600). Insets 
in E and I: Counter-staining with DAPI for fluorescent nucleus detection. Section G was 
counter-stained with toluidin blue. P: periosteum, CB: cortical bone, T: Trabecula. 
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Figure 5: Immunodetection of Plx-A3 during endochondral development of rat femur. 
A: E17, arrows: staining in the periosteum (X600); B: E19, diaphysis along the primary 
ossification centre (X200), selected areas enlarged in C (periosteum) and D (cortical bone); C 
and D: arrows: labeled profiles (X1000); E: E21, diaphysis (X100), selected area enlarged in 
F (X600); G: P14, ossification front, arrows: vascular buds (X800), enlarged in H (X1200); I: 
Non-immune control at E21; J: Trabecular bone in the metaphysis at P14; stars: lumen of 
labeled capillaries (X1000). All sections were counter-stained with toluidin blue. 
 
Figure 6: Immunodetection of NH and TH during endochondral development of rat 
femur. A: NH at E17; arrows: labeling in the periosteum (X200). B: NH at E19, diaphysis 
along the primary ossification center; long arrows: staining in the periosteum, short arrows: 
staining in the bone collar (X800). C: NH at E21, diaphysis (X800). D: Non-immune control 
at E21 (X600). E: NH at P14, periosteum of the diaphysis; arrows: staining (X800). F: TH at 
E17, metaphysis; arrows: labeling in the periosteum (X1200). G: TH at E19, diaphysis along 
the primary ossification center; long arrows: staining in the periosteum, short arrows: staining 
in the bone collar (X400). H: TH at E21, diaphysis (X1200). I: non-immune control at E21 
(X1200). All sections were counter-stained with toluidin blue. 
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